[1]
|
PNLS-INFO No. 001/2007 PNLS-Togo, 2007, 1-5.
|
[2]
|
PNLS, “Directives Pour une Prise en Charge Avec les Médicaments Antirétroviraux (ARV) au Togo,” 2004, pp 3-9.
|
[3]
|
PNLS, “Guide National de la Prise en Charge Médiacle du VIH/SIDA: Affections Opportunistes et Traitement par les Antirétroviraux,” 2004, p. 104.
|
[4]
|
OMS, “Recommendation Pour une Approche de Santé Publique: Améliorer L’accès aux Traitements Antirétroviraux dans les Pays à Ressources Limitées,” 2002, pp. 8-9.
|
[5]
|
ONUSIDA, “Rapport sur l’épidémie Mondiale de SIDA,” ONUSIDA, Genève, 2006, pp. 3-4.
|
[6]
|
R. D. Moore and J. C. Keruly, “CD4+ Cell Count 6 Years after Commencement of Highly Active Antiretroviral Therapy in Person with Sustained Virologic Suppression,” Clinical Infectious Diseases, Vol. 44, No. 3, 2007, pp. 441-446. http://dx.doi.org/10.1086/510746
|
[7]
|
J. V. Baker, G. Peng, J. Rapkin, et al., “CD4+ Count and Risk of Non-AIDS Diseases Following Initial Treatment for HIV Infection,” AIDS, Vol. 22, No. 7, 2008, pp. 841-888. http://dx.doi.org/10.1097/QAD.0b013e3282f7cb76
|
[8]
|
S. Emery, J. A. Neuhaus, A. N. Phillips, et al., “Major Clinical Outcomes in Antiretroviral Therapy (ART)-Naive Participants and in Those Not Receiving ART at Baseline in the SMART Study,” Journal of Infectious Diseases, Vol. 197, No. 8, 2008, pp. 1133-1144. http://dx.doi.org/10.1086/586713
|
[9]
|
HIV-CAUSAL Collaboration, et al., “The Effect of Combined Antiretroviral Therapy on the Overall Mortality of HIV-Infected Individuals,” AIDS, Vol. 24, No. 1, 2010, pp. 123-137. http://dx.doi.org/10.1097/QAD.0b013e3283324283
|
[10]
|
M. Guiguet, F. Boue, J. Cadranel, J. M. Lang, E. Rosenthal and D. Costagliola, “Effect of Immunodeficiency, HIV Viral Load, and Antiretroviral Therapy on the Risk of Individual Malignancies (FHDH-ANRS CO4): A Prospective Cohort Study,” Lancet Oncology, Vol. 10, No. 12, 2009, pp. 1152-1159. http://dx.doi.org/10.1016/S1470-2045(09)70282-7
|
[11]
|
C. F. Kelley, C. M. Kitchen, P. W. Hunt, et al., “Incomplete Peripheral CD4+ Cell Count Restoration in HIV Infected Patients Receiving Long-Term Antiretroviral Treatment,” Clinical Infectious Diseases, Vol. 48, No. 6, 2009, pp. 787-794. http://dx.doi.org/10.1086/597093
|
[12]
|
M. Egger, M. May, G. Chêne, et al., “Prognosis of HIV-1-Infected Patients Starting Highly Active Antiretroviral Therapy: A Collaborative Analysis of Prospective Studies,” Lancet, Vol. 360, No. 9327, 2002, pp. 119-129. http://dx.doi.org/10.1016/S0140-6736(02)09411-4
|
[13]
|
J. P. Phair, J. W. Mellors, R. Detels, J. B. Margolick and A. Munoz, “Virologic and Immunologic Values Allowing Safe Deferral of Antiretroviral Therapy,” AIDS, Vol. 16, No. 18, 2002, pp. 2455-2459. http://dx.doi.org/10.1097/00002030-200212060-00011
|
[14]
|
E. Wood, R. S. Hogg, B. Yip, et al., “Higher Baseline Levels of Plasma Human Immunodeficiency Virus Type 1 RNA Are Associated with Increased Mortality after Initiation of Triple-Drug Antiretroviral Therapy,” Journal of Infectious Diseases, Vol. 188, No. 10, 2003, pp. 1421-1425. http://dx.doi.org/10.1086/379201
|
[15]
|
Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group, et al., “Response to Combination Antiretroviral Therapy: Variation by Age,” AIDS, Vol. 22, No. 12, 2008, pp. 1463-1473. http://dx.doi.org/10.1097/QAD.0b013e3282f88d02
|
[16]
|
A. H. Greenbaum, L. E. Wilson, J. C. Keruly, R. D. Moore and K. A. Gebo, “Effect of Age and HAART Regimen on Clinical Response in an Urban Cohort of HIV-Infected Individuals,” AIDS, Vol. 22, No. 17, 2008, pp. 2331-2339. http://dx.doi.org/10.1097/QAD.0b013e32831883f9
|